US · CRDL
Cardiol Therapeutics Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Oakville, ON L6H 0G5
- Website
- cardiolrx.com
Price · as of 2024-12-31
$1.37
Market cap 113.91M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $5.10 | ||||
| 2019 | $2.32 | ||||
| 2020 | $3.73 | ||||
| 2021 | $1.32 | ||||
| 2022 | $0.50 | $23.36 | |||
| 2023 | $1.50 | ||||
| 2024 | $1.16 |
AI valuation
Our deep-learning model estimates Cardiol Therapeutics Inc.'s (CRDL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.37
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CRDL | Cardiol Therapeutics Inc. | $1.37 | 113.91M | — | — | — | — | -3.18 | 4.71 | — | -2.15 | -19.96 | 4.71 | 0.00% | — | — | -138.47% | 660.06% | -106.99% | 0.01 | — | 4.52 | 4.41 | 0.76 | 1591.00% | — | -64.00% | -21.53% | -3.58 | 411.05% | 0.00% | 0.00% | 0.00% | -2.14 | -3.43 | — | -1.32 |
| ASRT | Assertio Holdings, Inc. | $11.66 | 74.82M | +1,017% | +6,046% | -82% | +159% | -3.44 | 0.61 | 0.59 | 2.82 | — | 1.83 | 68.61% | -19.59% | -17.27% | -16.66% | -29.57% | -7.56% | 0.33 | -8.05 | 1.77 | 1.34 | -2.01 | -9507.00% | -1783.00% | -4608.00% | 35.54% | 0.23 | 31.91% | 0.00% | 0.00% | 0.47% | -0.59 | 0.55 | 0.12 | -2.51 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| HYPR | Hyperfine, Inc. | $1.07 | 81.53M | +2,340% | -64% | — | — | -1.74 | 1.45 | 5.51 | -0.80 | — | 1.45 | 45.70% | -335.33% | -315.90% | -61.03% | -410.39% | -53.19% | 0.01 | — | 6.15 | 5.26 | 0.89 | -968.00% | 1684.00% | -813.00% | -55.17% | -4.44 | -371.71% | 0.00% | 0.00% | 0.00% | -0.78 | -0.86 | 2.61 | -3.97 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| IMA | ImageneBio Inc | $6.72 | 75.14M | +440% | +18% | — | +475% | -16.94 | 6.62 | 238.26 | -20.21 | — | 6.62 | 100.00% | -1057.14% | -1044.80% | -33.30% | -524.86% | -29.52% | 0.06 | — | 11.80 | 11.54 | 0.90 | -3742.00% | -6179.00% | -4261.00% | -5.52% | -4.27 | -652.59% | 0.00% | 0.00% | 0.00% | -19.38 | -15.59 | 204.87 | 28.99 |
| INCR | InterCure Ltd. | $0.83 | 45.39M | +740% | -23% | — | +1,093% | -3.53 | 0.65 | 1.08 | -7.60 | -80.10 | 1.49 | 12.66% | -28.14% | -28.38% | -17.09% | -10.38% | -9.40% | 0.53 | -3.26 | 1.73 | 1.14 | -2.59 | 441.00% | -3282.00% | 2676.00% | -27.72% | -0.30 | -13.21% | 0.00% | 0.00% | 0.00% | -5.80 | -5.47 | 1.63 | 0.20 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| MBOT | Microbot Medical Inc. | $2.41 | 109.82M | — | — | — | — | -1.98 | 6.43 | — | -1.53 | — | 6.43 | 0.00% | — | — | -284.97% | 667.72% | -159.40% | 0.03 | — | 2.37 | 2.35 | 0.26 | -3048.00% | — | 334.00% | -39.02% | -3.59 | 508.44% | 0.00% | 0.00% | 3.38% | -1.49 | -1.96 | — | -21.36 |
| NSPR | InspireMD, Inc. | $1.78 | 75.42M | +1,242% | -35% | — | — | -3.72 | 3.30 | 16.99 | -2.61 | — | 3.30 | 21.49% | -478.00% | -456.63% | -84.68% | -1143.45% | -67.77% | 0.06 | — | 5.28 | 4.80 | 0.50 | -732.00% | 1296.00% | 3887.00% | -19.54% | -2.85 | -794.20% | 0.00% | 0.00% | 7.17% | -2.59 | -3.73 | 12.38 | -2.29 |
| VANI | Vivani Medical, Inc. | $1.23 | 72.67M | — | — | — | — | -2.53 | 3.37 | — | -2.49 | — | 3.37 | 0.00% | — | — | -122.42% | -125.35% | -53.77% | 1.10 | — | 3.41 | 3.11 | -0.04 | -1400.00% | — | -1319.00% | -35.94% | -3.47 | -108.41% | 0.00% | 0.00% | 0.00% | -2.45 | -2.83 | — | -4.16 |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- CEO
- David G. Elsley
- Employees
- 18
- Beta
- 0.69
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.37) − 1 = — (DCF, example).